Inhibition of angiogenesis by a novel small peptide consisting of the active fragments of platelet factor-4 and vasostatin.
Inhibition of angiogenesis provides a potential anti-cancer therapy. Here we describe a novel recombinant peptide composed of active fragments of two distinct angiogenesis inhibitors, platelet factor-4 (C-13 fragment) and vasostatin (N-terminal amino acids 135-164) with a nonpolar peptide bridge of Gly-Pro-Gly. This fusion peptide showed significantly enhanced efficacy compared with its parent peptides in inhibiting human endothelial cell proliferation and neovasculerization in chick embryo chorioallantoic membrane. The data suggest that making a single recombinant peptide containing the active fragments of multiple angiogenesis inhibitors is a promising approach to developing a better anti-angiogenetic therapy.
Li
Xiaokun
X
School of Pharmaceutical Science, Wenzhou Medical College, Wenzhou 325035, PR China.
Jiang
Lijuan
L
Wang
Yi
Y
Xiao
Yechen
Y
Huang
Yadong
Y
Yao
Qiongfeng
Q
Yang
Yongguang
Y
Wu
Xiaoping
X
D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D000818:Animals; D037282:Calreticulin / Q000494:pharmacology*; D049109:Cell Proliferation / Q000187:drug effects; D002478:Cells, Cultured; D002642:Chick Embryo; D049033:Chorioallantoic Membrane / Q000098:blood supply; D004730:Endothelium, Vascular / Q000187:drug effects*; D006801:Humans; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D010446:Peptide Fragments / Q000494:pharmacology*; D010978:Platelet Factor 4 / Q000494:pharmacology*; D011993:Recombinant Fusion Proteins / Q000494:pharmacology*
D020533:Angiogenesis Inhibitors; D037282:Calreticulin; D010446:Peptide Fragments; D011993:Recombinant Fusion Proteins; C121986:vasostatin; D010978:Platelet Factor 4